Heat shock protein 90 (Hsp90) has emerged as a promising target for the treatment of cancer, Alzheimer's and Parkinson's diseases, motor impairments, multiple sclerosis, and other disorders. Progress toward the development of both N and C-terminal inhibitors is described.